A. V. Ramanan Et Al. , "Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.," Lancet (London, England) , vol.402, no.10401, pp.555-570, 2023
Ramanan, A. V. Et Al. 2023. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.. Lancet (London, England) , vol.402, no.10401 , 555-570.
Ramanan, A. V., Quartier, P., Okamoto, N., Foeldvari, I., Spindler, A., Fingerhutová, Š., ... Antón, J.(2023). Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.. Lancet (London, England) , vol.402, no.10401, 555-570.
Ramanan, Athimalaipet Et Al. "Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.," Lancet (London, England) , vol.402, no.10401, 555-570, 2023
Ramanan, Athimalaipet V. Et Al. "Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.." Lancet (London, England) , vol.402, no.10401, pp.555-570, 2023
Ramanan, A. V. Et Al. (2023) . "Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.." Lancet (London, England) , vol.402, no.10401, pp.555-570.
@article{article, author={Athimalaipet V Ramanan Et Al. }, title={Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.}, journal={Lancet (London, England)}, year=2023, pages={555-570} }